Close this search box.

Amphista degrades a cancer target using a non-traditional ligase

ARTICLE | Product Development

Amphista’s targeted glues combine the advantages of PROTACs and molecular glues to create selective, orally bioavailable therapies

By Danielle Golovin, Senior Biopharma Analyst

May 23, 2024 11:18 AM UTC

Amphista has revealed data showing it can degrade a cancer target using a “targeted glue” that recruits a non-traditional E3 ligase, with superior bioavailability compared with cereblon-based degraders.

Molecular glues have historically been found serendipitously, meaning the MOA is discovered after showing efficacy.